Alterity Therapeutics Ltd ATHE
Alterity Therapeutics Ltd (Nasdaq: ATHE) is a CNS/neurology/psychiatry drug developer. Its lead program, ATH434, is in Phase 2 for Multiple System Atrophy (MSA). Its next catalyst on record is ATH434: Initiation of Phase 3 trial activities in MSA (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ATH434 — Initiation of Phase 3 trial activities in MSA (2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ATH434 | Multiple System Atrophy | small molecule | Phase 2 |
| ATH434 | Parkinson's disease | small molecule | Pre-clinical |
| Next-generation zinc ionophores / discovery library | various (cancer, neurological, infectious disease) | small molecule | Pre-clinical |
Recent results and decisions
- Oct 15, 2026n/a Alterity Therapeutics approves changes to CEO Dr. David Stamler's remuneration package effective October 15, 2026.
The Board confirms that it has approved changes to Dr Stamler's total remuneration package effective from 15 October 2026.
Filing - Jul 30, 2026n/a FDA End-of-Phase 2 meeting minutes confirmed a registrational pathway: a single pivotal Phase 3 trial plus confirmatory evidence could support approval (approx. 200 patients, 1:1, 50 mg vs placebo, 12 months, UMSARS Part I primary).
FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.